CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Regional Chemotherapy for the Treatment of Breast Cancer: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines

Last updated: October 12, 2018
Project Number: RC1029-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report


  1. What is the clinical effectiveness of regional chemotherapy for adults with metastatic breast cancer?
  2. What is the cost-effectiveness of regional chemotherapy for adults with metastatic breast cancer?
  3. What are the evidence-based guidelines associated with the use of regional chemotherapy for the treatment of adults with metastatic breast cancer?

Key Message

Evidence of very limited quality from six non-randomized studies indicated that regional chemotherapy may provide benefit with regard to tumour response and survival; however, additional evidence from high quality, randomized controlled trials is required to better assess whether regional chemotherapy offers a benefit relative to conventional and other therapies. Studies showed that regional chemotherapy was minimally associated with toxicity.No evidence regarding cost-effectiveness or evidence-based guidelines describing regional chemotherapy for metastatic breast cancer was identified.